iSpecimen Inc. (NASDAQ: ISPC)

iSpecimen is a technology driven company that operates a global marketplace platform connecting life science researchers with human biospecimens and associated data. The company’s mission is to accelerate life science research discovery and development by providing researchers with streamlined access to biofluids tissues and living cells sourced from healthcare provider organizations worldwide. iSpecimen’s platform aggregates de identified patient and specimen data from electronic medical records laboratory information systems biobank inventories and other sources creating a searchable inventory that enables users to locate specimens matching specific study criteria. By offering a single online interface for search selection ordering and tracking iSpecimen aims to transform the fragmented biospecimen procurement process into a more efficient and transparent workflow.

iSpecimen generates revenue by procuring specimens from its network of healthcare providers and distributing those annotated biospecimens to research clients. The company does not charge fees for use of the marketplace platform or for marketing sales contracting and compliance services; instead it earns a margin on each transaction by sharing a portion of the proceeds with the supplying organization according to pre agreed revenue share arrangements that range from twenty percent to fifty percent depending on specimen type collection requirements and data provided. Revenue is derived from a variety of specimen categories including remnant biofluids remnant tissue remnant hematopoietic stem and immune cells next generation sequenced tissues research use only biofluids research use only tissue and research use only hematopoietic stem and immune cells. The company follows a just in time model acquiring specimens only after receiving a customer order which minimizes inventory risk and aligns costs with demand.

iSpecimen operates in a highly fragmented biospecimen procurement market where many healthcare providers commercial biobanks specimen brokers and specialized suppliers offer limited access to their own inventories. Most individual participants control less than five percent of the total market and no single entity exceeds a twenty percent share giving iSpecimen a relative advantage through its aggregated network approach. The company’s competitive strengths stem from its technology platform that standardizes data from diverse sources provides intuitive search and workflow tools and manages compliance and administrative functions on behalf of both researchers and suppliers. By offering end to end order management and real time data integration iSpecimen reduces the time and cost associated with specimen acquisition while enhancing transparency. Its global reach spanning fourteen countries and its ability to deliver usage insights further strengthen its position relative to competitors that rely on manual processes or localized inventories.

iSpecimen serves primarily biopharmaceutical companies in vitro diagnostic companies and government or academic institutions engaged in life science research. As of December 31 2025 the company had distributed specimens to approximately seven hundred seventy six customers across twenty three countries including notable entities such as the Centers for Disease Control and Prevention. The customer base is diversified though a small subset of regenerative medicine clients contributed a modest share of revenue in both 2024 and 2025. Geographic concentration shows that the majority of revenue originates in the Americas with a smaller portion coming from Europe the Middle East and Africa and the Asia Pacific region. During the year ended December 31 2025 a single customer accounted for roughly twenty percent of total revenue while in the prior year one customer represented about twenty nine percent of sales indicating some concentration among top accounts. Customer retention remains moderate with less than half of the top twenty five customers from the previous year continuing to purchase specimens in the following period.